126 related articles for article (PubMed ID: 16180530)
1. [New challenges in multiple sclerosis].
Regenauer A
Versicherungsmedizin; 2005 Sep; 57(3):115-21. PubMed ID: 16180530
[TBL] [Abstract][Full Text] [Related]
2. [Multiple sclerosis. An update with practical guidelines for ophthalmologists].
Ziemssen T; Wilhelm H; Ziemssen F
Ophthalmologe; 2006 Jul; 103(7):621-41; quiz 642-3. PubMed ID: 16819666
[TBL] [Abstract][Full Text] [Related]
3. [Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No].
Edan G
Rev Neurol (Paris); 2013 Nov; 169(11):864-8. PubMed ID: 24125462
[TBL] [Abstract][Full Text] [Related]
4. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
5. Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline?
Marziniak M; Ghorab K; Kozubski W; Pfleger C; Sousa L; Vernon K; Zaffaroni M; Meuth SG
Mult Scler Relat Disord; 2016 Jul; 8():35-44. PubMed ID: 27456872
[TBL] [Abstract][Full Text] [Related]
6. Using MRI to make informed clinical decisions in multiple sclerosis care.
Bermel RA; Naismith RT
Curr Opin Neurol; 2015 Jun; 28(3):244-9. PubMed ID: 25887772
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics.
Leist TP; Marks S
Neurology; 2010 Jan; 74 Suppl 1():S54-61. PubMed ID: 20038764
[TBL] [Abstract][Full Text] [Related]
8. Adherence to MRI protocol consensus guidelines in multiple sclerosis: an Australian multi-centre study.
Curley M; Josey L; Lucas R; Dear K; Taylor BV; Coulthard A; ; Chapman C; Coulthard A; Dear K; Dwyer T; Kilpatrick T; Lucas R; McMichael T; Pender MP; Ponsonby AL; Taylor B; Valery P; van der Mei I; Williams D
J Med Imaging Radiat Oncol; 2012 Dec; 56(6):594-8. PubMed ID: 23210577
[TBL] [Abstract][Full Text] [Related]
9. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.
Harris JO; Frank JA; Patronas N; McFarlin DE; McFarland HF
Ann Neurol; 1991 May; 29(5):548-55. PubMed ID: 1859184
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis update.
Markowitz CE
Am J Manag Care; 2013 Nov; 19(16 Suppl):s294-300. PubMed ID: 24494618
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials].
Ozawa K; Saida T
Rinsho Shinkeigaku; 1995 Dec; 35(12):1501-3. PubMed ID: 8752444
[TBL] [Abstract][Full Text] [Related]
13. [Noninflammatory pathogenesis of lesions in multiple sclerosis].
Kornhuber ME
Nervenarzt; 2006 Aug; 77(8):989-90; author reply 990-2. PubMed ID: 16838074
[No Abstract] [Full Text] [Related]
14. [Age-related macular degeneration--new options for therapy?].
Bornfeld N
Klin Monbl Augenheilkd; 2005 May; 222(5):379-80. PubMed ID: 15912453
[No Abstract] [Full Text] [Related]
15. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.
Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Verdun E; Bradac GB; Riva A; Geuna M; Bergamini L
Mult Scler; 1995; 1 Suppl 1():S32-7. PubMed ID: 9345396
[TBL] [Abstract][Full Text] [Related]
16. [Magnetic resonance imaging in multiple sclerosis].
Tourbah A; Berry I
Pathol Biol (Paris); 2000 Mar; 48(2):151-61. PubMed ID: 10815291
[TBL] [Abstract][Full Text] [Related]
17. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
Barkhof F; Scheltens P; Frequin ST; Nauta JJ; Tas MW; Valk J; Hommes OR
AJR Am J Roentgenol; 1992 Nov; 159(5):1041-7. PubMed ID: 1414773
[TBL] [Abstract][Full Text] [Related]
18. [Quality of life and care of members of the Saxonian branch of the German Society for Multiple Sclerosis. Results of a written questionnaire].
Voigt K; Worm I; Klewer J; Twork S; Kugler J;
Gesundheitswesen; 2007; 69(8-9):457-63. PubMed ID: 17926262
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
